A medical device to save the arms and legs of U.S.
military personnel from amputation became the first of its kind to win
U.S. marketing clearance by the U.S. Food and Drug Administration
(FDA). The military
hopes the Temporary Limb Salvage Shunt will reduce the number of arm and
leg amputations and improve the quality of life of other patients who
suffer injuries, according to Air Force Lieutenant Colonel Todd Rasmussen,
Chief of Military Vascular Surgery at Wilford Hall Medical Center in San
Antonio, the Air Force’s largest medical facility. The military
plans to use the devices in Iraq in one or two soldiers per
week. The United
States is the first country to grant clearance for use of the device, said
Mac Ritchie, Vice-President, Vascutek Ltd. The device is designed and
manufactured by Renfrew, Scotland-based Vascutek Ltd., a division of
Terumo Corporation.
“There was a critical
need for this device,” said David Buckles, Chief of
FDA’s peripheral device branch. “We think it has a
chance of working very well and improving the chances of salvaging a limb
that has suffered this sort of traumatic injury.”
The device works by connecting the ends of a severed blood
vessel, providing a bridge or shunt around the damaged area and restoring
blood flow to the injured limb. It can be implanted on the battlefield and
other remote areas to bypass damaged blood vessels and temporarily
maintain blood flow to the injured limb until the patient can be
transported to a surgical facility. Six percent of the
14,120 soldiers injured in Iraq between March 2003 and August 2005 --
equivalent to 28 soldiers per month – had arm or leg
amputations, according to the AEI-Brookings Joint Center for Regulatory
Studies in Washington.
Vascutek, Ltd., a wholly owned
subsidiary of Terumo Corporation, Japan, is one of
the world's leading designers, manufacturers and marketers of vascular
products for the treatment of cardiovascular
disease. Its U.S. operations are based in
Ann Arbor, Michigan. It is one of a family of Terumo companies
focused on cardiac and vascular disease, along with Terumo Cardiovascular
Systems Corporation, developer and manufacturer of cardiac surgery
devices, and Terumo Heart, developer of a ventricular assist
device. For more information, visit
www.vascutek.com
Terumo Corporation is a premier
global medical company with 2006 annual sales in excess of $2.1 billion.
For more information, visit www.terumo.com.
Terumo Cardiovascular Systems
Corporation manufactures and markets products for cardiac surgery. It is
headquartered in Ann Arbor, Michigan with American manufacturing
operations in Ann Arbor, as well as Elkton, Maryland; Ashland,
Massachusetts; and Tustin, California. For more information,
visit www.terumo-cvs.com
|